Clinical Trials Logo

Hypophosphatemia clinical trials

View clinical trials related to Hypophosphatemia.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06112236 Active, not recruiting - Hypophosphatemia Clinical Trials

Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Start date: February 17, 2023
Phase:
Study type: Observational

The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.

NCT ID: NCT05509595 Active, not recruiting - Clinical trials for Fibrous Dysplasia Of Bone

Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Start date: December 7, 2022
Phase: Phase 2
Study type: Interventional

Background: Fibrous dysplasia (FD) is a disorder that affects bone growth. Affected bone tissue is weakened, and people with FD are prone to deformities, fractures, and other problems. People with FD may also have low blood phosphate levels. This can make bones even weaker. Better treatments are needed. Objective: To test a study drug (burosumab) in people with FD who have low blood phosphate levels. Eligibility: People aged 1 year or older who have FD and low blood phosphate levels. Design: Participants will visit the NIH 3 times in 48 weeks. Each visit will last 5 to 7 days. Participants will self-inject burosumab under the skin in their belly, upper arm, or thigh. They (or a caregiver) will do this at home 1 or 2 times a month. They will be trained in person on how to inject the drug. Home injections will be guided via telehealth. During NIH visits, participants will have a physical exam with blood and urine tests. They will have x-rays of different parts of their body. They will have a radioactive tracer injected into their vein; then they will have a bone scan. They will have tests to assess their strength, walking, and movement. They will complete questionnaires about their pain, mobility, and fatigue levels. Adult participants may have bone biopsies. These will be done under anesthesia with sedation. Small samples of FD-affected bone will be removed for study. Between NIH visits, participants will go to a local laboratory for blood and urine tests. Child participants will have an additional follow-up visit 2 weeks after the final NIH visit.

NCT ID: NCT04946409 Active, not recruiting - Clinical trials for X Linked Hypophosphatemia

Burden of Disease and Functional Impairment in XLH

IdeFIX
Start date: October 1, 2020
Phase:
Study type: Observational

Observational study comprising prospective follow up as well as retrospective chart review in order to evaluate the longitudinal course of the disease in XLH patients with a specific focus on functional impairment, physical performance and complications associated with the disease or respective treatment.

NCT ID: NCT04842032 Active, not recruiting - Clinical trials for X-linked Hypophosphatemia (XLH)

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

Start date: November 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH

NCT ID: NCT04842019 Active, not recruiting - Clinical trials for X-linked Hypophosphatemia (XLH)

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

Start date: September 28, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with XLH

NCT ID: NCT03993821 Active, not recruiting - Clinical trials for Epidermal Nevus Syndrome

Burosumab for CSHS

Start date: July 1, 2019
Phase: Early Phase 1
Study type: Interventional

Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. This drug is already approved for use in patients with X-linked hypophosphatemia (XLH), but not for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). It is hypothesized that burosumab may provide clinical benefit to a patient with CSHS due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.

NCT ID: NCT03976440 Active, not recruiting - Acute Renal Failure Clinical Trials

Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study

Start date: June 1, 2019
Phase:
Study type: Observational

The aim of the study are: 1) To evaluate the occurrence of acid-base alterations and the incidence of hypophosphatemia during different modalities of Renal Replacement Terapy (RRT) in critically ill patients [CVVH, CVVHDF and SLED (Sustained Low-Efficiency Dialysis)] by using a simplified Regional Citrate Anticoagulation (RCA) protocol combined with the adoption of a phosphate-containing solution as dialysate and/or replacement fluid; 2) To optimize the infusion rates of different solutions adopted, including citrate, in order to obtain an appropriate electrolyte and buffer supply. The final aim of this approach will be to reduce the need for frequent monitoring of acid-base status and electrolytes (with special regard to ionized calcium levels), and to avoid the need for frequent adjustments of RCA-RRT parameters (infusion rate of different solutions, electrolytes supplementation in the course of RRT). This approach could allow to simplify anticoagulation protocols with citrate, in order to minimize potential concerns hampering a wider diffusion of RCA in daily practice.

NCT ID: NCT03745521 Active, not recruiting - Clinical trials for X-Linked Hypophosphatemia

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

SUNFLOWER
Start date: May 1, 2018
Phase:
Study type: Observational

Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1. To determine medical characteristics of the disease and the disease process 2. To determine physical and psychological burden on patients as well as economic burden 3. To assess the efficacy and safety of the treatment of the disease

NCT ID: NCT03651505 Active, not recruiting - Clinical trials for X-linked Hypophosphatemia

X-linked Hypophosphatemia Disease Monitoring Program

Start date: July 16, 2018
Phase:
Study type: Observational

The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.

NCT ID: NCT03193476 Active, not recruiting - Clinical trials for X-Linked Hypophosphatemia

Registry for Patients With X-Linked Hypophosphatemia

Start date: September 12, 2017
Phase:
Study type: Observational [Patient Registry]

This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The main objective of this XLH Registry is to collect data to characterise the treatment, progression and long-term outcomes of XLH in both adult and paediatric settings.